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Statins: An essential component in the
management of carotid artery disease
Kosmas I. Paraskevas, MD, FASA,a George Hamilton, MD, FRCS,b and
Dimitri P. Mikhailidis, MD, FFPM, FRCPath, FRCP,c London, United Kingdom
Objective: We aimed to define the role of treatment using statins (3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors) in the management of patients with carotid artery disease.
Literature Search Methods: We searched PubMed for studies evaluating the effect of statins on carotid IMT and the
occurrence of cerebrovascular events.
Literature Search Results: Current evidence indicates that routine statin therapy reduces carotid intima-media thickness
progression and stroke risk. Additionally, statin treatment significantly reduces perioperative as well as long-term
morbidity and mortality in patients undergoing carotid surgery or endovascular interventions. It would also be expected
that statins would reduce coronary events in this high-risk population.
Conclusions: Statins should be considered as an essential component of the therapeutic approach of patients with carotid
artery stenosis. ( J Vasc Surg 2007;46:373-86.)With 700,000 events/year, stroke is the third leading
cause of death in the United States.1,2 In 2002, a total of
162,672 deaths from stroke occurred among US residents,
with an age-adjusted death rate of 56.2 per 100,000 pop-
ulation.1
Early studies reported an association between low-
density lipoprotein (LDL) cholesterol and carotid intima-
media thickness (IMT).3,4 There is also evidence showing
that carotid IMT is a strong predictor of the occurrence of
carotid atherosclerosis, coronary heart disease (CHD), and
future cerebrovascular events.5-9 Therefore, lipid lowering
treatment could have a beneficial effect on these condi-
tions. Candidate drugs for this role are statins (3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors), a fam-
ily of lipid lowering drugs known to exert several beneficial
actions.10-16 Statins are safe, with liver failure and rhabdo-
myolysis the only serious adverse effects, occurring at a rate
of only one case per million person-years.17,18 Statins are
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We aimed to define the role of routine statin therapy in
patients with carotid artery disease by focusing on two
parameters: (1) The effect of statins on carotid IMT and
carotid artery disease progression rates, and, (2) The overall
effect of these drugs on stroke and cardiovascular events
rates.
LITERATURE SEARCH METHODS
We searched PubMed for studies evaluating the effect
of statins on carotid IMT and the occurrence of cerebro-
vascular events. The search terms used were “statins”,
“stroke”, “carotid intima-media thickness”, “carotid artery
stenosis”, “carotid atherosclerosis”, “cerebrovascular
events,” and “carotid artery disease” in various combina-
tions. The selected reports were manually searched and
relevant publications obtained from their reference lists
were retrieved.
All studies reporting results from statin therapy on
carotid IMT progression/stroke rates were included in our
analysis. Two studies were not included in our survey:
(1) The first study20 was excluded due to the small number
of patients in the statin and placebo groups (n 10 for
each) and the joint administration of estriol. In this
context, there is evidence that noncontraceptive estro-
gen use is associated with IMT regression (9 m/
y).21 Consequently, the reported beneficial effect on
carotid IMT progression rate cannot be solely attrib-
uted to statin therapy in this study.
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August 2007374 Paraskevas et alTable I. Trials investigating the effect of statins on carotid IMT rates of progression (The trials are
arranged chronologically.)
Study (year and number
of patients)
Study drug
(study duration) Main outcome(s)
ACAPS39 (1994,
n  919)
Lovastatin vs placebo
(3 yrs)
A significant reduction of mean carotid IMT progression was achieved in the lovastatin
group (mean IMT: 0.009  0.003 mm/yr; P  .001).
PLAC-II40 (1995,
n  151)
Pravastatin vs
placebo (3 yrs)
a) Progression of mean-maximum IMT: 0.059 vs 0.068 mm/yr for statin and placebo
(12% reduction), respectively (P  .44).
b) Progression of CCA IMT: 0.0295 vs 0.0456 mm/yr for statin and placebo (35%
reduction), respectively, (P  .03).
KAPS41 (1995,
n  424)
Pravastatin vs
placebo (3 yrs)
A 45% (95% CI 16%-69%) reduction in the annual rate of atherosclerotic progression
in the CCA and carotid bulb (0.017 vs 0.031 mm/yr, for pravastatin and placebo,
respectively, P  .005).
CAIUS23 (1996,
n  305)
Pravastatin vs
placebo (3 yrs)
Progression of mean maximum carotid IMT: 0.0043 vs 0.0089 mm/yr, for
pravastatin and placebo, respectively (P  .0007).
MARS24 (1996,
n  188)
Lovastatin vs placebo
( 4 yrs)
a) Mean IMT reduction at 2 yrs: 0.038  0.004 vs 0.019  0.004 mm/yr, for
lovastatin and placebo, respectively (P  .001),
b) Mean IMT reduction at 4 yrs: 0.028  0.003 vs 0.015  0.005 mm/yr, for
lovastatin and placebo, respectively (P  .001).
LIPID25 (1998,
n  522)
Pravastatin vs
placebo (4 yrs)
a) After 2 yrs: Mean carotid wall thickness: 0.039 mm in the placebo group and was
essentially unchanged in the pravastatin group [0.049-mm (SE  0.01) difference
between groups; P  .003].
b) After 4 yrs: Mean carotid wall thickness: 0.048 vs 0.014 mm for the placebo
and the pravastatin groups, respectively [0.062-mm (SE  0.01) difference between
groups; 2P  .0001].
REGRESS26 (1998,
n  255)
Pravastatin vs
placebo (2 yrs)
The mean combined IMT decreased by 0.05 mm in the pravastatin group and
remained unchanged in the placebo group (P  .0085).
ACAPS27 (1999,
n  919)
Lovastatin /
warfarin vs placebo
(34.1 mo)
Carotid IMT regression:
In women: 0.0066 vs 0.0057 mm/yr, for lovastatin vs placebo, respectively (P
 .09).
In men: 0.0151 vs 0.0005 mm/yr, for lovastatin and placebo, respectively (P 
.02)
Combination therapy: 0.0104 vs 0.0057 mm/yr, for lovastatin  warfarin vs
placebo, respectively (P  .02).
Davis et al28 (2000,
n  12)
Atorvastatin (8 wks) The median IMT was reduced by 15.3% [from 0.98 (95% CI  0.68 - 1.18) to 0.83
(95% CI  0.65 - 0.99) mm; P  .001].
BCAPS42 (2001,
n  793)
Fluvastatin and/or
Metoprolol CR/
XL* vs placebo
(36 mo)
a) Compared with placebo, fluvastatin (but not metoprolol) significantly reduced the
mean IMT rate of progression (Mean difference between groups: 0.009 mm; P 
.002.).
b) Fluvastatin (as well as metoprolol) significantly reduced the composite variable
consisting of the mean CCA IMT and the change in the maximum IMT in the
carotid bulb after 36 mo of treatment (0.011 mm/yr; 95% CI  0.022 to
0.001; P  .034).
ASAP (2001,29 200330)
(n  325)
Atorvastatin vs
simvastatin (2 yrs)
Carotid IMT: Significantly (P  .0017) decreased by atorvastatin (mean decrease:
0.031 mm; 95% CI  0.007 to 0.055), and significantly (P  .0005)
increased by simvastatin (mean increase: 0.036 mm; 95% CI  0.014 - 0.058). The
difference between the two groups was highly significant (P  .0001).
Hegland et al31 (2001,
n  230)
Simvastatin
(33.17.8 mo)
A mean 13.5% regression in the carotid stenosis was noted in the simvastatin group
(mean follow-up: 32.6  6.2 mo), while a mean 6.4% progression of carotid
stenosis was observed in the untreated group (mean follow-up: 33.1  7.8 mo, P 
.001).
Youssef et al32 (2002,
n  25)
Atorvastatin (8 wks) CCA IMT was significantly reduced by 8-week atorvastatin treatment (from 0.79 
0.21 to 0.64  0.15 mm; P  .024).
ARBITER33 (2002,
n  161)
Pravastatin vs
atorvastatin (1 yr)
Mean carotid IMT reduction: from 0.625  0.188 to 0.591  0.145 mm vs from
0.615  0.145 to 0.640  0.150 mm, for atorvastatin and pravastatin, respectively,
or 0.034  0.021 vs 0.025  0.017 mm reduction, for atorvastatin and
pravastatin, respectively (P  .03).
FAST34 (2002,
n  246)
Probucol vs
pravastatin vs diet
(2 yrs)
a) Carotid IMT: 13.9% in the pravastatin group (P  .01 by Friedman’s test) vs
23.9% in the control group (P  .05 by Friedman’s test).
b) The change in IMT was significantly greater in the probucol and pravastatin groups
than in the control group (both P  .001).
c) No significant difference in IMT changes between probucol and pravastatin after 24
mo.
Corti et al35 (2002,
n  21)
Simvastatin (2 yrs) Simvastatin treatment resulted in a significant reduction in maximum carotid artery
wall thickness (from 2.65  0.9 to 2.14  0.6 mm; P  .001).
Beishuizen et al46
(2004, n  182)
Cerivastatin vs
placebo (24 mo)
No significant change in mean carotid IMT for statin compared with placebo (from
0.763  0.124 to 0.765  0.116 mm; P  .78, and from 0.780  0.129 to 0.774
 0.124 mm; P  .50, at 2 yrs for statin and placebo, respectively).
as the
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Study] trial) was not included due to unsuccessful
randomization.
LITERATURE SEARCH RESULTS
Statins and carotid IMT progression rates.
Studies investigating the effect of statins on carotid IMT
progression rate are listed in Table I (Appendix 1, online
Table I. Continued.
Study (year and number
of patients)
Study drug (study
duration)
Ito et al47(2004,
n  36)
Cerivastatin vs
pravastatin vs diet
No significant di
(cerivastatin: 1
1.8% increase [
0.89  0.26 to
PHYLLIS43 (2004,
n  508)
Hydrochlorothiazide
/ pravastatin,
fosinopril /
pravastatin (2.6
yrs)
a) Hydrochlorot
 0.004 mm/
b) Fosinopril alo
mm/yr (P  .
c) Hydrochlorot
difference  
d) Fosinopril  p
0.012 mm/
HYRIM44 (2005,
n  285).
Fluvastatin vs
placebo (4 yrs).
a) Fluvastatin sig
(0.049 vs 0.07
b) Carotid bulb
(mean differen
Reid et al36 (2005,
n  54).
Pravastatin vs
placebo (9 mo).
- Carotid IMT at
respectively (P
- Carotid IMT at
respectively (P
Takahashi et al45 (2005,
n  45).
Simvastatin vs
pravastatin vs
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a) Simvastatin sig
IMT compare
1.011  0.160
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to 1.040  0.1
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Yokoyama et al37(2005,
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Watanabe et al48 (2005,
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Maximum caroti
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Ainsworth et al338
(2005,
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Atorvastatin vs
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Rate of progressi
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PREVEND IT49 (2005,
n  642).
Pravastatin vs
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b) Mean change
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ACAPS, Asymptomatic Carotid Artery Progression Study; yrs, years; IMT,
Carotid Arteries-II Study; CCA, common carotid artery; KAPS, Kuopi
Atherosclerosis Italian Ultrasound Study;MARS, Monitored Atheroscleros
Disease Study; SE, standard error; REGRESS, Regression Growth Evalua
Lowering Asymptomatic Plaque Study; ASAP, Atorvastatin versus Sim
Investigation of the Treatment Effects of Reducing Cholesterol; FAST, Fuku
Study; HYRIM, Hypertension High Risk Management Study; PREVEND
*CR/XL: Controlled Release/Extended Release.
†CBMmax : CBMmax was the primary outcome in this study. It was defined
common carotids and bifurcations bilaterally.only). The vast majority demonstrated a significant re-gression of carotid IMT after statin therapy.23-38 In
several others,39-45 statin treatment resulted in a signif-
icant reduction of carotid IMT progression rates. Only a
few trials failed to show a significant difference between
statin and placebo groups.46-49 Two meta-analysis8,50
reported an overall decrease in IMT following statin
treatment. The first one including 90,000 participants
in statin trials showed that there was a strong correlation
Main outcome(s)
ce in carotid IMT was seen between the 3 modalities after 6 mo
ncrease [from 0.87  0.21 to 0.88  0.22 mm], pravastatin:
1.09  0.36 to 1.11  0.38 mm], diet: 1.1% increase [from
 0.24 mm]).
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tatin and placebo, respectively (P not significant).
T: 0.039  0.009 vs 0.035  0.009 mm, for pravastatin and
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ession Study; LIPID, Long-term Intervention with Pravastatin in Ischemic
tatin Study; mo, months; wks, weeks; BCAPS, Beta-Blocker Cholesterol-
n on Atherosclerosis Progression; ARBITER, Arterial Biology for the
herosclerosis Trial; PHYLLIS, PlaqueHypertension Lipid-Lowering Italian
evention of Renal and Vascular End Stage Disease Intervention Trial.
rate of change in mean maximum IMT of the 8 far and near walls in distalfferen
.1% i
from
0.90
hiazid
yr.
ne vs
03).
hiazid
0.01
ravas
yr, P
nifica
6 mm
IMT
ce: 
6 m
 .0
9 m
 .0
nifica
d with
to 1
uced
con
59 m
d a m
right
T de
it incr
vastat
d IM
sed b
.
on of
astat
from
ravas
in IM
ctivel
intima
o Ath
is Regr
tion S
vastati
oka At
IT, Prbetween LDL lowering and carotid IMT reduction (r 
JOURNAL OF VASCULAR SURGERY
August 2007376 Paraskevas et alTable II. Trials investigating the effect of statins on stroke rates (The trials are arranged chronologically.)
Study (year and number
of patients)
Study drug (study
duration) Main outcome(s)
4S51(1994,
n  4444)
Simvastatin vs placebo
(5.4 yrs)
Fatal or nonfatal cerebrovascular events (TIA, unclassified, intervention-
associated, hemorrhagic, embolic and nonembolic stroke): 70 vs 98 pts, for
simvastatin and placebo, respectively (relative risk: 0.70; 95% CI  0.52 - 0.96;
P  .024).
LRT63(1994,
n  404)
Lovastatin vs placebo
(6 mo)
a) Incidence of stroke: 0% vs 0.5%, for lovastatin and placebo, respectively (P 
.50).
b) Number of events: 0 vs 1, for lovastatin and placebo, respectively (P  .50).
ACAPS39(1994,
n  919)
Lovastatin vs placebo
(3 yrs)
Number of strokes: 0 vs 4, for lovastatin and placebo, respectively (P  .05).
WOSCOP64(1995,
n  6595)
Pravastatin vs placebo
(4.9 yrs)
Number of strokes: 46 (6 fatal) vs 51 (4 fatal), for pravastatin and placebo,
respectively (risk reduction: 11%; 95% CI  –33% to 40%; P  .57).
PLAC I65 (1995,
n  408)
Pravastatin vs placebo
(3.0 yrs)
Number of strokes: 0 vs 2, for pravastatin and placebo, respectively (P  .21)
KAPS41 (1995,
n  424)
Pravastatin vs placebo
(3 yrs)
Number of strokes: 2 vs 4, for pravastatin and placebo, respectively (P not
significant, P value not mentioned)
REGRESS66 (1995,
n  885)
Pravastatin vs placebo
(2 yrs)
Number of cerebrovascular events (strokes and TIAs): 3 vs 5, for pravastatin and
placebo, respectively (P not significant, P value not mentioned).
CARE52 (1996,
n  4159)
Pravastatin vs placebo
(5.0 yrs)
Incidence of stroke: 2.6% vs 3.8% (or 54 vs 78 pts), for pravastatin and placebo,
respectively (risk reduction: 31%; 95% CI  3% - 52%; P  .03).
Post-CABG67 (1997,
n  1351)
Aggressive vs
moderate lova-statin
(4.3 yrs)
Number of strokes: 18 vs 16, or 2.3% vs 2.2%, in the aggressive and moderate
lovastatin groups, respectively (P  .48).
AFCAPS/TexCAPS68
(1998,
n  6605)
Lovastatin vs placebo
(5.2 yrs)
Incidence of stroke: 14 vs 17, for lovastatin and placebo, respectively (P not
significant).
LIPID (1998,
252000)53(n  9014)
Pravastatin vs placebo
(6.1 yrs)
a) Incidence of stroke: 3.7% vs 4.5%, for pravastatin and placebo, respectively (risk
reduction: 19%; 95% CI  0 - 34%; P  .048)
b) Fatal strokes: 22 vs 27, for pravastatin and placebo, respectively (P  .001).
c)Nonhemorrhagic strokes: 3.4% vs 4.4%, for pravastatin and placebo, respectively
(risk reduction: 23%; 95% CI  5 - 38%; P  .02).
SCAT69 (2000,
n  460)
Simvastatin /
Enalapril vs placebo
(4.0 yrs)
Incidence of stroke: 2% vs 3% (or 4 vs 7 events), for simvastatin and placebo,
respectively (P  .544).
GISSI70(2000,
n  4271)
Pravastatin vs placebo
(23.0  6.7 mo)
Number of strokes: 20 vs 19, for the pravastatin and placebo groups, respectively
(P not significant).
MIRACL (2001,54
2002)55 (n  3086)
Atorvastatin vs placebo
(16 wks)
a) Number of strokes: 12 vs 24, for atorvastatin and placebo, respectively (relative
risk: 0.49; 95% CI  0.24 - 0.98; P  .045).
b) Nonfatal strokes: 9 vs 22 pts for atorvastatin and placebo, respectively (relative
risk: 0.40; 95% CI  0.19 - 0.88; P  .02).
ALLHAT71(2002,
n  10,355)
Pravastatin vs no statin
(4.8 yrs)
Number of strokes: 209 vs 231 events for pravastatin and placebo, respectively
(relative risk: 0.91; 95% CI  0.75 - 1.09; P  .31).
HPS56(2002,
n  20,536)
Simvastatin vs placebo
(5.0 yrs)
a) Incidence of fatal or nonfatal first stroke: 4.3% vs 5.7%, or 444 vs 585 pts, for
simvastatin and placebo, respectively (P  .0001).
b) Incidence of ischemic stroke was reduced by 30% (290 vs 409 pts or 2.8% vs
4.0% for simvastatin and placebo, respectively, P  .0001).
GREACE57(2002,
n  1600)
Atorvastatin vs placebo
(3.0 yrs)
Fatal and nonfatal strokes: 9 vs 17 in the atorvastatin and placebo groups,
respectively (risk reduction: 0.53; 95% CI  0.30 - 0.82; P  .034)
PROSPER72 (2002,
n  5804)
Pravastatin vs placebo
(3.2 yrs)
Number of strokes: 135 vs 131 for pravastatin and placebo, respectively (HR 
1.03; 95% CI  0.81 - 1.31; P  .8).
ASCOT-LLA58 (2003,n
 10,305)
Atorvastatin vs placebo
(3.3 yrs)
Fatal and nonfatal strokes: 89 vs 121 in the atorvastatin and placebo groups,
respectively (HR  0.73; 95% CI  0.56 - 0.96; P  .024)
REVERSAL73 (2004,
n  654)
Pravastatin vs
atorvastatin (18 mo)
Number of strokes: 1 vs 1 (or 0.3% for both groups) for pravastatin and
atorvastatin respectively.
ALLIANCE74 (2004,
n  2442)
Atorvastatin vs usual
care (54.3 mo)
Number of strokes: 35 vs 39 (or 2.9% vs 3.2%) for the atorvastatin and usual care
groups, respectively (HR  0.87; 95% CI  0.55 - 1.38; P  .552).
CARDS59 (2004,
n  2838)
Atorvastatin vs placebo
(3.9 yrs)
Incidence of stroke: 1.5% vs 2.8% (or 21 vs 35 pts.) for atorvastatin and placebo,
respectively (HR: 0.52; 95% CI  0.31 - 0.89; P  .001)
A to Z trial75 (2004,
n  4497)
Intensive vs less
intensive simva-
statin therapy (2 yrs)
Number of strokes: 28 vs 35 (or 1.8% and 1.3%) for the intensive and less
intensive statin regimen groups, respectively (P  .36).
PROVE IT-TIMI-2276
(2004,
n  4162)
Standard-dose
pravastatin vs high-
dose atorvastatin
Rates of stroke: 1.0% vs 1.0% for high- vs standard-dose statin, respectively.(24 mo)
ve Lip
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was estimated to reduce carotid IMT by 0.73% per year
[95% confidence Interval (CI)  0.27-1.19].8 The other
meta-analysis including 10 trials and a total of 3443
individuals showed that statin therapy significantly re-
duced the rate of carotid atherosclerosis progression.50
The total weighted mean difference of carotid IMT
progression between patients receiving statins vs placebo
was 22.35% (95% CI  from 18.14 to 26.56%, P 
.00001).
Statins and stroke rates. Studies investigating the effect
of statins on stroke rates are listed in Table II (Appendix 2,
online only). Several trials reported a significant reduction in
the incidence of stroke rates after statin therapy;25,39,51-62
others failed to show the superiority of statins compared with
placebo.41,63-77 The vast majority of these trials recruited
patients with CHD;25,51-55,57,60,62,63,65,67,69,70,73-77 other
trials were based on primary prevention,41,58,59,64,68,71,72 or
included patients with diabetes59 or with evidence of carotid
disease.39 Only two trials (HPS [Heart Protection Study]56
and SPARCL [Stroke Prevention by Aggressive Reduction in
Cholesterol Levels]61) included patients with previous stroke
or transient ischemic attacks (TIAs).
A meta-analysis including over 90,000 individuals par-
ticipating in statin trials demonstrated that statin treatment
significantly reduced the incidence of stroke.8 Each 10%
reduction in LDL cholesterol was estimated to reduce the
risk of all strokes by 15.6% (95% CI  6.7-23.6).8 A similar
meta-analysis (n  90,056 participants) showed that statin
treatment was associated with a significant 17% propor-
Table II. Continued.
Study (year and number
of patients)
Study drug (study
duration)
TNT (2005,60 200662)
(n  10,001)
High- vs low-dose
atorvastatin (4.9
yrs)
a) Fatal or n
high-dose
P  .02).
b) Incidence
252 pts.)
0.64 - 0.9
IDEAL77 (2005,
n  8888)
Atorvastatin vs
simvastatin
(median: 4.8 yrs)
Fatal or non
atorvastat
SPARCL61 (2006,
n  4731)
Atorvastatin vs
placebo (4.9 yrs)
Incidence of
atorvastat
adjusted H
4S, Scandinavian Simvastatin Survival Study; yrs, years; TIA, Transient Ischem
mo, months;ACAPS, Asymptomatic Carotid Artery Progression Study;WO
and Atherosclerosis in the Carotid Arteries-I Study;KAPS, Kuopio Atherosc
CARE, Cholesterol and Recurrent Events Trial; Post-CABG, Post Coron
Atherosclerosis Prevention Study; LIPID, Long-term Intervention with Pra
rosis Trial; GISSI, Gruppo Italiano per lo Studio della Sopravvivenza nell’
Cholesterol Lowering; wks, weeks; ALLHAT, Antihypertensive and Lipid-L
GREACE, GREek Atorvastatin and Coronary-Heart-Disease Evaluation; PR
ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering
ALLIANCE, Aggressive Lipid-Lowering Initiation Abates New Cardiac
IT-TIMI-22, Pravastatin or Atorvastatin Evaluation and Infection Therapy
targets; IDEAL, Incremental Decrease in End Points Through Aggressi
Cholesterol Levels.tional reduction in the incidence of first fatal or nonfatalstroke of any type (hemorrhagic, ischemic, or of unknown
type; 1340 vs 1617 events, for statin vs placebo, respec-
tively; 95% CI 12% - 22%, P .0001) per mmol/l lower
LDL cholesterol.78
Clinical (vascular) events. The effect of statins on the
composite of myocardial infarction (MI), coronary events
and vascular death reported in these studies is listed in
Table III (Appendix 3, online only). Statin treatment was
associated with a significant reduction in vascular events, as
well as in vascular and overall mortality. A recent meta-
analysis with over 90,000 participants in statin trials showed
that statin therapy was associated with a 12% proportional
reduction in all-cause mortality per mmol/L reduction in
LDL cholesterol (95% CI  9%-16%, P  .0001).78 This
reflected a significant 19% reduction in coronary mortality
(95% CI  15%-24%, P  .0001), and nonsignificant
reductions in noncoronary vascular mortality (7%, 95% CI
3% to 17%, P .2) and nonvascular mortality (5%, 95%
CI  1% to 10%, P  .1). Furthermore, there was a
corresponding 23% reduction in MI or coronary death
(95% CI  20%-26%, P  .0001), and a 24% reduction in
the need for coronary revascularization (95% CI  20%-
27%, P  .0001).
DISCUSSION
The results of our literature search indicate that statins not
only favorably modulate carotid IMT progression, but also
reduce the risk of stroke and combined cardiovascular events.
It is worth noting that in the studies included in this
review, there was considerable variation in the effect of
Main outcome(s)
al strokes: 155 vs 117 (or 3.1% vs 2.3%) for the low-dose and
astatin groups, respectively (HR  0.75; 95% CI  0.59 - 0.96;
rebrovascular events (stroke or TIA): 3.9% vs 5.0% (or 196 vs
and low-dose atorvastatin, respectively (HR: 0.77; 95% CI 
.007)
trokes: 174 vs 151 (or 3.9% vs 3.4%) for simvastatin and
pectively (HR  0.87; 95% CI  0.70 - 1.07; P  .20)
or nonfatal stroke: 11.2% vs 13.1% (or 265 vs 311 pts.) for
placebo, respectively (5-year absolute risk reduction: 2.2%,
0.84; 95% CI  0.71 - 0.99; P  .03).
tack; pts, patients;CI, confidence interval; LRT, Lovastatin Restenosis Trial;
, West of Scotland Coronary Prevention Study; PLAC I, Pravastatin, Lipids,
Prevention Study;REGRESS, Regression Growth Evaluation Statin Study;
rtery Bypass Graft Trial; AFCAPS/TexCAPS, Air Force/Texas Coronary
in in Ischemic Disease; SCAT, Simvastatin/Enalapril Coronary Atheroscle-
Miocardico; MIRACL, Myocardial Ischemia Reduction with Aggressive
ng Treatment to Prevent Heart Attack Trial; HPS, Heart Protection Study;
R, Prospective Study of Pravastatin in the Elderly at Risk;HR, hazard ratio;
REVERSAL, Reversal of Atherosclerosis with Aggressive Lipid Lowering;
ts Study; CARDS, Collaborative Atorvastatin Diabetes Study; PROVE
mbolysis in Myocardial Infarction 22 Investigators; TNT, treating to new
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August 2007378 Paraskevas et alin both the statin and the placebo groups. As the inclusion
criteria were different in various studies, so was the out-
come in terms of IMT change and incidence of stroke. The
death (The trials are arranged chronologically.)
Study (year and number of
patients ) Study drug (study duration)
ACAPS39 (1994, n  919) Lovastatin vs placebo
(3 yrs)
PLAC-II40 (1995, n  151) Pravastatin vs placebo
(3 yrs)
AFCAPS/ TexCAPS68
(1998, n  6605)
Lovastatin vs placebo
(5.2 yrs)
LIPID (1998)145 (2000)53
(n  9014)
Pravastatin vs placebo
(6.1 yrs)
HPS56 (2002, n  20,536) Simvastatin vs placebo
(5 yrs)
PROVE IT-TIMI-2276
(2004, n 4 162)
Standard-dose pravastatin
vs high-dose atorvastatin
(24 mo)
CARDS59 (2004, n  2838) Atorvastatin vs placebo
(3.9 yrs)
SPARCL61 (2006, n 
4731)
Atorvastatin vs placebo
(median: 4.9 yrs)
TNT60 (2006, n  10,001) Atorvastatin high- vs low-
dose (4.9 yrs)
ACAPS, Asymptomatic Carotid Artery Progression Study; yrs, years; CH
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries-II Study; A
TIAs, transient ischemic attacks; LIPID, Long-term Intervention with P
IT-TIMI-22, Pravastatin or Atorvastatin Evaluation and Infection Therapy
Collaborative Atorvastatin Diabetes Study; HR, Hazard Ratio; CI, confiden
Levels; TNT, treating to new targets.
*Any CHD: Acute coronary event, coronary revascularization, or angina/is
†Major coronary event includes CHD death, nonfatal procedure-related Mpatients recruited varied considerably; for example, somewere recruited because of hypercholesterolemia, CHD or
carotid stenosis; some had diabetes mellitus and some did
not. In addition, it is possible that other factors (ie, diet,
Main outcome(s)
r cardiovascular events (CHD mortality, nonfatal MI, or stroke)
curred in 5 vs 14 pts in the lovastatin and placebo groups,
spectively (P  .04).
60% reduction in clinical coronary events (4 vs 10, or 5.3% vs
.2%, P  .09) and fewer deaths (3 vs 5) for pravastatin and
acebo, respectively.
61% reduction in the combined end point of any coronary event
d any death (5 vs 13 and 7% vs 17%, respectively, P  .04) for
avastatin and placebo, respectively.
l number of fatal and nonfatal cardiovascular events (including
able angina, thrombotic cerebrovascular accidents, TIAs, and
ripheral arterial vascular disorders) in the lovastatin and placebo
oups was 194 and 255, respectively (P  .003).
r a period of 6.1 yrs, it was estimated that 30 deaths, 28 nonfatal
Is, and 9 nonfatal strokes were avoided (with allowance for
ultiple events in each patient) in 48 pts for every 1000 randomly
signed to treatment with pravastatin.
ause mortality was significantly reduced (1328 [12.9%] deaths
ong 10,269 allocated simvastatin vs 1507 [14.7%] among
,267 allocated placebo; P  .0003).
-dose atorvastatin was beneficial compared with standard-dose
avastatin: - 14% reduction in the need for coronary
vascularization (P  .04), - 29% reduction in the risk of
current unstable angina (P  .02), and - Marginally significant
duction in the rates of death from MI (18%, P  .06), or any
use (28%, P  .07)].
cidence of acute coronary event: 3.6% vs 5.5% (or 51 vs 77 pts.)
r atorvastatin and placebo, respectively (HR: 0.64; 95% CI 
45 - 0.91; P  .001)
eath from any cause: 4.3% vs 5.8% (or 61 vs 82 pts.) for
orvastatin and placebo, respectively (HR: 0.73; 95% CI  0.52 -
01; P  .059)
ajor coronary events: 81 vs 120, or 3.4% vs 5.1%, for
orvastatin and placebo, respectively; adjusted HR  0.65; 95%
I  0.49 - 0.87; P  .003.
ajor cardiovascular events: 334 vs 407, or 14.1% vs 17.2%, for
orvastatin and placebo, respectively; adjusted HR 0.80; 95%
I 0.69 - 0.92; P  .002.
ny CHD:* 123 vs 204, or 5.2% vs 8.6%, for atorvastatin and
acebo, respectively; adjusted HR  0.58; 95% CI  0.46 - 0.73;
 .001.
HD death: 101 vs 127, or 2.0% vs 2.5%, for high- and low-dose
orvastatin, respectively (HR: 0.80; 95% CI  0.61 - 1.03; P 
87).
onfatal MI: 243 vs 308, or 4.9% vs 6.2%, for high- and low-dose
orvastatin, respectively (HR: 0.78; 95% CI  0.66 - 0.93; P 
04).
ajor coronary event:† 335 vs 418, or 6.7% vs 8.3%, for high- and
w-dose atorvastatin, respectively (HR: 0.80; 95% CI  0.69 -
92; P  .0019).
ronary heart disease, MI, myocardial infarction, pts; patients; PLAC-II,
S/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study;
atin in Ischemic Disease Study; HPS, Heart Protection Study; PROVE
mbolysis in Myocardial Infarction 22 Investigators; mo, months; CARDS,
erval; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol
ia.
resuscitated cardiac death.Table III. Trials investigating the effect of statins on the composite end-point of MI, coronary events and vascular
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account for the variations observed.
Statins: Mechanism of action with special reference to
carotid disease
Statins block the synthesis of isoprenoid intermedi-
ates, which serve as lipid attachments for a variety of
intracellular signaling molecules, especially Rho proteins
(small GTP-binding proteins).79-81 Rho proteins play
crucial roles in diverse cellular events, such as cytoskele-
ton organization, membrane trafficking, secretion, tran-
scriptional regulation as well as cell growth control and
development.80 Their proper membrane localization and
function are dependent on isoprenylation.79-81 By this
mechanism, statins exert actions which include improv-
ing or restoring endothelial function, inhibiting the pro-
liferation and migration of smooth muscle cells (SMCs),
inhibiting the secretion of several matrix metalloprotein-
ases (MMPs) from SMCs and macrophages, decreasing
vascular inflammation, and enhancing the stability of
atherosclerotic plaques.79,80,82-87
Early animal studies showed a beneficial effect of statins
on carotid IMT.88-90 One mechanism of action, demon-
strated in both experimental studies on human macro-
phages91 and animal models,92 is the marked suppression
of tissue factor (TF). TF is a transmembrane glycoprotein
that binds factor VII/VIIa, thus, triggering the down-
stream coagulation pathway that leads to fibrin deposi-
tion.93 TF participates in the development of atheroscle-
rotic lesions and also mediates their thrombogenicity.94
Fluvastatin was shown to exert direct nonlipid-related an-
tithrombotic effects at the level of the arterial intima by
reducing TF levels in experimental atherosclerotic lesions
of cholesterol-fed rabbits without concomitant changes in
serum cholesterol levels.92
In a study investigating the effect of statins on carotid
plaque stabilization, all carotid plaques from 137 patients
undergoing carotid endarterectomy (CEA) were col-
lected.95 Of the study group, 52 (38%) received a statin for
6 weeks before CEA. Plaque concentrations, measured in
ng/g wet weight of plaque, were significantly lower in the
group of patients on statin therapy for MMP-1 (23 vs 39
ng/g, P .0176), MMP-9 (120 vs 308 ng/g, P .0018),
and interleukin (IL)-6 (1,372 vs 2,732 ng/g, P  .0005).
In addition, the MMP-1/Tissue Inhibitor of matrix metal-
loproteinase (TIMP)-1 and MMP-9/TIMP-1 ratios were
significantly lower in the statin group (2.1 vs 4.5, P .031,
and 24 vs 49, P  .002 for statin users vs nonusers,
respectively), implying decreased net proteolysis.
A recent study showed that statin therapy results in a
significant increase of carotid echogenicity, indicating im-
provement of plaque stability.48 At a molecular level, statins
(atorvastatin) were also shown to reduce the expression of
prostaglandin E2 receptors in atherosclerotic plaques and
blood mononuclear cells in patients with carotid stenosis and
in cultured monocytic cells.96 The inhibition of prostaglandin
E2 receptors could explain, at least in part, the mechanism by
which statinsmodulate the cyclo-oxygenase-2/ prostaglandinE synthase-1 proinflammatory pathway and favor plaque sta-
bilization in humans.
In addition to promoting plaque stability,48,96,97
statins reduce platelet reactivity.98-101 Platelet deposition
on carotid plaque plays a role in the pathophysiology of
thromboembolic stroke by promoting thromboembo-
lism.102 The precise mechanism involved is not yet clear;
suggested theories implicate decreased platelet thrombox-
ane A2 production,
98 or reductions in LDL cholesterol and
effects on the platelet Na/H antiport system.103,104
A different mechanism of action of statins demon-
strated in animal models involves up-regulation of brain
endothelial nitric oxide (NO) synthase (eNOS).105-107 Im-
paired NO synthesis or activity accompanies hypercholes-
terolemia and other risk factors for vascular disease.108 NO
is a potent endothelial antiatherosclerotic factor; its func-
tions include inhibition of leukocyte and platelet adhesion,
control of vascular tone and growth, and maintenance of a
thrombo-resistant interface between the bloodstream and
the vessel wall.105-108
Other effects of statins have also been reported; for
example, increased plaque collagen and decreased plaque
lipid content, reduced neointima formation, and increased
fibrinolytic activity.109-117 Whether the possible blood
pressure lowering effect attributed to statins also influences
stroke risk remains to be established.118
Statins and carotid IMT
Carotid IMT is a strong predictor for the development of
carotid plaques and carotid artery stenosis119 and is associated
with CHD, stroke, and cholesterol levels.6,7,119-121 Common
carotid IMT predicts the occurrence of atherosclerotic
carotid plaques;5 additionally, increased common carotid
artery IMT is associated with traditional cardiovascular risk
factors,122-124 the presence of atherosclerosis in other arte-
rial beds,125,126 and an increased risk of CHD and
stroke.5-9 Therefore, carotid IMT is a useful marker for the
extent of carotid, as well as generalized, atherosclerosis.
The positive effect of statin treatment on carotid IMT
was first reported more than a decade ago. A double-blind,
randomized clinical trial applying a 3-year protocol with
pravastatin or placebo on 151 coronary patients demon-
strated a nonsignificant (P  .44) 12% reduction in pro-
gression of the mean-maximum IMT and a statistically
significant (P  .03) 35% reduction in IMT progression in
the common carotid artery.127,128 The effect of long-term
(12-month129 or 3-year130) statin therapy on carotid
plaque stability occurs independently of cholesterol lower-
ing. Even short-term (8-week) statin therapy significantly
reduces carotid IMT.28,32
A meta-analysis including nine trials (2792 subjects in
total) investigating the effect of statin therapy on carotid
IMT progression showed a strong correlation between
LDL cholesterol lowering and carotid IMT reduction (r
0.65, P  .004).8 Each 10% reduction in LDL cholesterol
was estimated to reduce the carotid IMT by 0.73% per year
(95% CI 0.27-1.19). Another meta-analysis including 10
trials and a total of 3443 individuals also showed that statin
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rosis progression.50 The total weighted mean difference of
carotid IMT progression between patients receiving statins
vs placebo was 22.35% (95% CI  from 18.14% to
26.56%, P  .00001). The results of these meta-analyses
strongly suggest that statin therapy offers significant advan-
tages to patients with carotid artery disease.
The ARBITER (Arterial Biology for the Investigation of
the Treatment Effects of Reducing Cholesterol) 1,33 2,131
and 3132 trials demonstrated the importance not only of
LDL cholesterol reduction, but also of high-density li-
poprotein (HDL) cholesterol elevation. In ARBITER 1,33
atorvastatin 80 mg/day for 12 months resulted in 48.5%
decrease in LDL cholesterol (from 148  32 to 76  23
mg/dl). In contrast, pravastatin 40 mg/day for 12 months
resulted in 27.2% decrease in LDL cholesterol (from 155
34 to 110  30 mg/dl, P  .001 for between-group
comparison). Similarly, the effect of atorvastatin was signif-
icantly different from the effect of pravastatin regarding
carotid IMT (from 0.625 0.188 to 0.591 0.145mm vs
from 0.615 0.145 to 0.640 0.150, or0.034 0.021
vs 0.025  0.017 mm change, for atorvastatin and prava-
statin, respectively, P  .03). These results underline the
importance of maximal decrease in LDL cholesterol levels.
In ARBITER 2,131 the effect of adding extended-
release niacin to background statin therapy in patients with
known CHD was investigated. Both niacin and placebo
groups had low LDL cholesterol levels, with mean values
100mg/lt. After 12months, HDL cholesterol levels rose
significantly in the niacin group while they were unchanged
in the placebo group (from 39 7 to 47 16 mg/dl, P
.001, and from 40  7 to 40  9 mg/dl, P  .61, for the
niacin and the placebo groups, respectively). The increase
in carotid IMT in the niacin group was 0.014 0.104mm,
compared with 0.044 0.100mm in the placebo group (P
 .08). On paired analysis, the increase in carotid IMT
progression in the niacin group was not statistically signif-
icant (from 0.893  0.259 to 0.907  0.235 mm, P 
.23). In contrast, a significant increase in carotid IMT
progression in the placebo groupwas observed (from 0.868
 0.207 to 0.912  0.202 mm, P  .001).
In ARBITER 3, both placebo and niacin patients from
ARBITER 2 were switched to niacin and were followed up
for an additional 12 months.132 After 24 months of niacin
therapy (or 12 months for those who crossed over from
placebo), carotid IMT was significantly reduced in both
groups compared with baseline (0.040  0.12 mm, P 
.008). In conclusion, therapeutic targets probably need to
include both a reduction of LDL cholesterol levels and an
elevation of HDL cholesterol levels to achieve an optimal
decrease in carotid IMT progression.
Current evidence therefore suggests that carotid IMT
is a marker of systemic atherosclerosis and cardiovascular
risk.133 Carotid IMT is a surrogate marker for atheroscle-
rosis and a strong predictor of future vascular events.133
However, ultrasonography has limitations in estimating
carotid stenosis; assessing the extent of stenosis may be
biased depending on individual expertise. Nevertheless, theassociation between lowering LDL cholesterol and carotid
IMT reduction achieved by treatment with statins suggests
that these drugs exert beneficial effects in carotid artery
disease.
Statins and stroke rates
An early meta-analysis including 13 studies39-41,51,52,
63-66,134-138 (20,438 subjects; 87,481 person-years) showed
that of the 442 strokes reported, 181 were observed in the
patients randomized to treatmentwith a statin, and 261 in the
patients randomized to placebo (P  .001).139 An overall risk
reduction of 31% [odds ratio (OR)  0.69; 95% CI  0.57-
0.83] in favor of statin therapy was reported. The data sug-
gested that approximately 40 strokes could be prevented
when treating 10,000 patients with CHD with statins for a
considerable length of time.
The effect of statins on reducing the risk of stroke is also
supported by two more recent meta-analyses.8,78 In the
first meta-analysis,8 statin treatment significantly decreased
the risk of fatal or nonfatal stroke (P  .002).8 Each 10%
decrease in LDL cholesterol was estimated to reduce the
risk of all strokes by 15.6% (95% CI  6.7-23.6%). In the
second meta-analysis,78 an overall significant 17% decrease
(95% CI  12%-22%, P  .0001) was estimated in the
incidence of first fatal or nonfatal stroke of any type per
mmol/l LDL cholesterol reduction. A common finding in
both meta-analyses is that the effect of statins is related to
the extent of cholesterol reduction.
The recently published SPARCL (Stroke Prevention by
Aggressive Reduction in Cholesterol Levels) trial also
showed that atorvastatin 80 mg/day reduced the overall
incidence of stroke and cardiovascular events in patients (n
 4731) with recent stroke or TIA (1 to 6 months prior to
study entry) but no clinically evident CHD.61 The
SPARCL trial61 was not included in the meta-analyses
mentioned above.8,78,139 In contrast to SPARCL,61 in the
PROSPER (PROspective Study of Pravastatin in the El-
derly at Risk) trial72 treatment for 3.2-years with pravasta-
tin (40 mg/day) had no significant effect on the incidence
of stroke when compared with placebo (135 vs 131 patients
on pravastatin and placebo, respectively, hazard ratio [HR]
 1.03, 95% CI 0.81-1.31, P .8). One explanation for
the lack of benefit from statin therapy could be the higher
systolic blood pressure (157.8  22.2 and 156.5  20.4
mmHg in the pravastatin and placebo groups, respectively)
than expected.140-142 In this context, it may be relevant
that statins have been reported to lower blood pressure
(approximately by 2 to 5 mm Hg).140-141 A 2 mm Hg
reduction in systolic blood pressure may account for 15%
reduction in stroke incidence.142
Another trial showed that preprocedural statin treat-
ment is associated with a reduction of cardiovascular events
after carotid angioplasty and stenting (CAS) in patients
with symptomatic carotid stenosis.143 The frequency of
cardiovascular complications (composite of stroke, MI, and
death within 30 days after CAS) between 127 patients
without preprocedural statin treatment and that of 53
patients with preprocedural statin treatment at CAS was
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patients, the minor stroke rate was 16 of 180 (9%) patients,
the major stroke rate was 1 of 180 (0.5%) patients, and the
death rate was 2 of 180 (1%) patients. The incidence of
cardiovascular events (composite of stroke, MI, and death
within 30 days after CAS) was significantly different be-
tween patients with and those without preprocedural statin
treatment (4% vs 15%, respectively, P  .05). It can there-
fore be concluded that statin treatment also offers signifi-
cant advantages in patients undergoing CAS.
Regarding optimal statin dosage, a meta-analysis includ-
ing randomized clinical trials comparing intensive vs standard-
dose statin therapy demonstrated the superiority of using
high-dose statin.144 Four randomized trials were included in
the meta-analysis: (1) the A-to-Z75 (n  4497), (2) PROVE
IT-TIMI-2276 (n  4162), (3) TNT60 (n  10,001), and (4)
IDEAL77 (n  8888). Overall, 27,548 patients were ran-
domized to standard- or high-dose statin, as determined
by the individual trial. The pooled analysis for rates of
stroke yielded a significant odds reduction of 18% favor-
ing high-dose statin treatment (2.8% vs 2.3% for stan-
dard- and high-dose statin treatment, respectively, OR
0.82, 95% CI  0.71-0.96, P  .012). A significant
benefit of high-dose vs standard-dose statin therapy was
demonstrated for number of coronary deaths or any
cardiovascular event (16% reduction, 32.3% vs 28.8% for
standard- vs high-dose statin groups, respectively,
OR  0.84, 95% CI  0.80-0.89, P  .0000001) and
CHD death or MI (16.5% reduction, 32.3% vs 28.8% for
standard- vs high-dose statin groups, respectively, OR 
0.835, 95% CI  0.77-0.91, P  0.0001). A trend to
reduction was demonstrated for cardiovascular (12% reduc-
tion, 3.8% vs 3.3% for standard- vs high-dose statin groups,
respectively, OR  0.88, 95% CI  0.78-1.00, P  .054)
and all-cause mortality (6% reduction, 6.2% vs 5.9% for
standard- vs high-dose statin groups, respectively, OR 
0.94, 95% CI  0.85-1.04, P  .20).144
The beneficial effects achieved by statins on carotid
IMT progression, stroke rates and reduction in the com-
posite end-point of MI, coronary events, and vascular
death39,40,53,68,76,133,145 imply that routine statin treat-
ment has multiple advantages for patients with carotid
artery disease. Furthermore, a recent preliminary study
showed that statin therapy prior to an episode of ischemic
stroke is associated with smaller infarct volume onmagnetic
resonance imaging (MRI).146 Additionally, the Heart Pro-
tection Study (HPS) showed a significant 50% decrease in
CEA in patients receiving simvastatin (40 mg/day) com-
pared with placebo (42 vs 82 patients or 0.4% vs 0.8%,
respectively, P  .0003).56 All-cause mortality was signifi-
cantly reduced (1328 vs 1507 deaths, or 12.9% vs 14.7%,
for simvastatin and placebo, respectively, P  .0003).56 In
another study, patients receiving statin therapy  6 weeks
before CEA were less likely to have had recent symptoms
attributable to their carotid disease (amaurosis fugax and
transient ischemic attacks [TIAs]).108 Only three patients
(6%) on statin therapy had carotid territory symptoms in
the 4 weeks before CEA (two with TIAs, one with amau-rosis fugax) compared with 21 patients (25%) not on statins
(16 with TIAs, five with amaurosis fugax).108 This differ-
ence was significant (P  .0049).
Therefore, the benefits of statin therapy in patients with
carotid artery disease may extend beyond stroke preven-
tion.
Statins and reduction in MI, coronary events and
vascular death
The results of these studies are shown in Table III. A
detailed discussion of these findings is beyond the scope of
the present review that focuses on carotid artery disease.
Future perspectives
A large multicenter randomized controlled clinical
trial, the ENHANCE (Ezetimibe and Simvastatin in Hy-
percholesterolemia Enhances Atherosclerosis Regression)
trial is currently under way.147 It aims to assess the com-
bined effect of simvastatin (80 mg/day) and ezetimibe (10
mg/day) therapy on carotid IMT compared with statin
monotherapy after 2 years of treatment. The results of this
trial are expected to shed light on the optimal treatment of
carotid atherosclerosis.
The Carotid Atorvastatin Study in Hyperlipidemic
post-Menopausal women (CASHMERE) trial is another
ongoing double-blind, randomized trial, which aims to
investigate the effect of statin and hormone replacement
therapy in reducing the early progression of atherosclerosis
in postmenopausal women.148 It aims to compare the
effects of 12-month atorvastatin (80 mg/day) therapy
alone, oral 17beta-estradiol (1 or 2 mg/day) plus cyclic
dydrogesterone (10 mg) alone, and their combination vs
placebo on the progression of carotid IMT by using a
high-definition echotracking device.
The results of the METEOR (Measuring Effects on
intima media Thickness: an Evaluation Of Rosuvastatin)
study are expected to clarify the role of routine statin
treatment in low risk subjects with signs of subclinical
carotid atherosclerosis (carotid IMT 1.2, but IMT
3.5 mm).149
Medical therapy for carotid atherosclerosis including
aggressive use of statins, targeted blood pressure lowering,
and antithrombotic therapy,150,151 may reduce the need
for revascularization procedures.
CONCLUSIONS
Current evidence suggests that statins exert a signifi-
cant beneficial effect on carotid IMT progression and
stroke rates. Additionally, preoperative statin use is associ-
ated with better perioperative and long-termmorbidity and
mortality in patients undergoing carotid and other noncar-
diac vascular surgery.152-159 This includes improved early
and late CEA anatomic durability.160 Statin therapy is also
beneficial for patients either refusing or judged unsuitable
for CEA,161 as well as for those who undergo endovascular
procedures.143 These advantages make routine statin ther-
apy a first-line option in the management of carotid artery
disease. Despite this evidence, the recent Michigan Stroke
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survivors receive adequate lipid-lowering therapy at dis-
charge.162
Patients with stroke, TIA, and/or carotid artery disease
are also likely to have atherosclerosis elsewhere.61,163
Statins may therefore exert additional benefits that are
unrelated to carotid artery disease (eg, significantly reduced
risk of major coronary events) in such patients, as was
evident in the SPARCL study.61
Unless contraindicated,17,18 the diagnosis of carotid
artery disease should be followed by prompt initiation of
statin therapy. Current evidence144 suggests that high-dose
offers more advantages than standard-dose statin treatment
and may therefore be the preferred option. Ongoing trials
(eg, ENHANCE)147 will help establish if more aggressive
lowering of LDL cholesterol using combination therapy
(eg, statin  ezetimibe) will achieve better results than
statin monotherapy. There is already some evidence that
simultaneous improvement of LDL and HDL cholesterol
was more effective than LDL lowering alone.131,132 There
is clearly a need for further research in this field.
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Study (Year)
Number of
patients Study design
ACAPS39
(1994)
919 patientsa
(445 women,
474 men)
- Initially: lovastatin
20 mg/day
- At 4.5 months up to
3 years: increased to
40 mg/day
Ev
PLAC-II40
(1995)
151 patients (75
on pravastatin,
vs. 76 on
placebo)
Pravastatin 20 mg/
dayb vs. placebo for
3 years
Ev
KAPS41
(1995)
424 patientsc
(212 on
pravastatin, vs.
212 on
placebo)
Pravastatin 40 mg/
day vs. placebo for 3
years
LD
CAIUS23
(1996)
305 patientsd
(151 on
pravastatin, 154
on placebo)
Pravastatin 40 mg/
day vs. placebo for 3
years
H
MARS24
(1996)
188 patients (99
on pravastatin,
89 placebo)
Lovastatin 80mg/day
vs. placebo for  4
years
CH
LIPID25
(1998)
522 patients (273
on pravastatin,
249 on
placebo)
Pravastatin 40 mg/
day vs. placebo for 4
years
M
REGRESS26
(1998)
255 men 70
yearse
Pravastatin 40 mg/
day vs. placebo for 2
years
H
ACAPS27
(1999)
919 patientsb
(445 women,
474 men)
Lovastatin 10-40 mg/
day / warfarin 1
mg/day vs. placebo
for 34.1 months
Ev
Davis et al28
(2000)
12 patients Atorvastatin 20 mg/
day for 8 weeks
Pratins on carotid IMT rates of progression
Inclusion criteria Main Outcome and Results
idence of early carotid
atherosclerosis using B-
mode ultrasonography
A significant reduction of mean carotid
IMT progression was achieved in the
lovastatin group (mean IMT:
0.009  0.003 mm/yr; P 
.001).
ident CHD or recent MI
and LDL cholesterol 130
mg/dl
a) Progression of mean-maximum
IMT: 0.059 vs. 0.068 mm/yr for
statin and placebo (12% reduction),
respectively (P  .44).
b) Progression of CCA IMT: 0.0295
vs. 0.0456 mm/yr for statin and
placebo (35% reduction), respec-
tively, (P  .03).
L cholesterol  4.0
mmol/l and total
cholesterol 7.5 mmol/lt
A 45% (95% CI  16%-69%) reduction
in the annual rate of atherosclerotic
progression in the CCA and carotid
bulb (0.017 vs. 0.031 mm/yr, for
pravastatin and placebo, respectively,
P  .005).
ypercholesterolemia and
evidence of early carotid
atherosclerosis using B-
mode ultrasonography
Progression of mean maximum carotid
IMT: 0.0043 vs. 0.0089 mm/yr,
for pravastatin and placebo,
respectively (P  .0007).
D and evidence of early
carotid atherosclerosis
using B-mode
ultrasonography
a) Mean IMT reduction at 2 years:
0.038  0.004 vs. 0.019 
0.004 mm/yr, for lovastatin and
placebo, respectively (P  .001),
b) Mean IMT reduction at 4 years:
0.028  0.003 vs. 0.015 
0.005 mm/yr, for lovastatin and
placebo, respectively (P  .001).
I or hospitalization for
unstable angina
a) After 2 years: Mean carotid wall
thickness: 0.039 mm in the pla-
cebo group and was essentially un-
changed in the pravastatin group
[0.049-mm (SE  0.01) difference
between groups; P  .003].
b) After 4 years: Mean carotid wall
thickness: 0.048 vs. 0.014 mm
for the placebo and the pravastatin
groups, respectively [0.062-mm
(SE  0.01) difference between
groups; 2P  .0001].
ypercholesterolemia (155-
310 mg/dl) and coronary
atherosclerosis as defined
by coronary angiography
The mean combined IMT decreased
by 0.05 mm in the pravastatin group
and remained unchanged in the
placebo group, P  .0085
idence of early carotid
atherosclerosis using B-
mode ultrasonography
Carotid IMT regression:
In women: 0.0066 vs. 0.0057
mm/yr, for lovastatin therapy alone
vs. placebo, respectively (P  .09)
In men: 0.0151 vs. 0.0005 mm/
yr, for lovastatin and placebo,
respectively (P  .02)
Combination therapy: 0.0104 vs.
0.0057 mm/yr, for lovastatin 
warfarin vs. placebo, respectively (P
 .02)
imary hypercholesterolemia
and PAD
After 8 weeks of atorvastatin
treatment, the median IMT was
reduced by 15.3% [from 0.98 (95%
CI  0.68 - 1.18) mm to 0.83 (95%
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Study (Year)
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patients Study design Inclusion criteria Main Outcome and Results
BCAPS42
(2001)
793 patients (199
on metoprolol,
198 on
fluvastatin, 197
on both, 199
on placebo)
Fluvastatin 40 mg/
day and/or
Metoprolol CR/
XLf 25 mg/day or
placebo for 36
months
Evidence of early carotid
atherosclerosis using B-
mode ultrasonography.
a) Compared with placebo, fluvastatin
(but not metoprolol) significantly
reduced the mean IMT rate of pro-
gression (Mean difference between
groups: 0.009 mm; P  .002.).
b) Fluvastatin (as well as metoprolol)
significantly reduced the composite
variable consisting of the mean
CCA IMT and the change in the
maximum IMT in the carotid bulb
after 36 months of treatment
(0.011 mm/yr; 95% CI 
0.022 to 0.001; P  .034).
ASAP
(2001)29
(2003)30
325 patients [160
on atorvastatin,
165 on
simvastatin]
Atorvastatin 80 mg/
day vs. simvastatin
40 mg/day for 2
years
Familial hypercholesterolemia - Atorvastatin therapy significantly
decreased carotid IMT (mean de-
crease: 0.031 mm, 95% CI 
0.007 to 0.055; P  .0017).
- Simvastatin therapy significantly in-
creased carotid IMT (mean increase:
0.036 mm, 95% CI  0.014 - 0.058;
P  .0005).
- The difference between the two
groups was highly significant (P 
.0001).
Hegland
et al31
(2001)
230 patients (318
carotids, 147
on simvastatin
vs. 171 no
treatment)
Simvastatin mean
dose: 27  11 mg/
day for 33.17.8
months
Patients with 1
measurement of  40%
stenosis in 1 or both
internal carotid arteries,
not referred for CEA and
without carotid occlusion.
- After a mean follow-up of 33.1 
7.8 months, a mean 6.4% progres-
sion of carotid stenosis was observed
in the untreated group.
- In the simvastatin group, a mean
13.5% regression in the carotid ste-
nosis was noted after a mean fol-
low-up of 32.6  6.2 months (P 
.001).
Youssef
et al32
(2002)
25 hyperlipidemic
patients with
PAD
Atorvastatin 20 mg/
day for 8 weeks
Hyperlipidemia and PAD CCA IMT was significantly reduced by
8-week atorvastatin treatment (from
0.79  0.21 to 0.64  0.15 mm, P
 .024)
ARBITER33
(2002)
161 patientsg (82
on pravastatin,
79 on
atorvastatin)
Pravastatin 40 mg/
day vs. atorvastatin
80 mg/day for 1
year
Hypercholesterolemia Mean carotid IMT reduction: from
0.625  0.188 to 0.591  0.145
mm vs. from 0.615  0.145 to
0.640  0.150 mm, for atorvastatin
and pravastatin, respectively, or
0.034  0.021 vs. 0.025  0.017
mm reduction, for atorvastatin and
pravastatin, respectively (P  .03).
FAST34
(2002)
246 patients (82
on probucol,
83 on
pravastatin, 81
on placebo)
Probucol 500 mg/day
or pravastatin 10
mg/day vs. diet
alone for 2 years
Primary hypercholesterolemia a) Carotid IMT: 13.9% in the prava-
statin group (P  .01 by Fried-
man’s test) vs. 23.9% in the con-
trol group (P  .05 by Friedman’s
test).
b) The change in IMT was signifi-
cantly greater in the probucol and
pravastatin groups than in the con-
trol group (both P  .001).
c) No significant difference in IMT
changes between probucol and
pravastatin after 24 months.
Corti et al35
(2002)
21 patients with
32 carotid
plaques
Simvastatin therapy
(dose not supplied)
for 2 years
Primary hypercholesterolemia
and ultrasound
documented thoracic aortic
or carotid artery
- Simvastatin treatment resulted in a
significant reduction in maximum
carotid artery wall thickness com-
pared with baseline (from 2.65 atherosclerotic plaques 0.9 to 2.14  0.6 mm, P  .001).
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Beishuizen
et al46
(2004)
182 patientsh
(103 on statin,
79 on placebo)
Cerivastatin 0.4 mg/
day or placebo for
24 monthsi
Type 2 diabetes and no
history of CHD
- Statin therapy did not induce a sig-
nificant change in mean carotid IMT
compared with placebo (from 0.763
 0.124 to 0.765  0.116 mm, P 
.78, and from 0.780  0.129 to
0.774  0.124 mm, P  .50, at 2
years for statin and placebo respec-
tively).
Ito et al47
(2004)
36 patients (13
on cerivastatin,
12 on
pravastatin, 11
on diet)
Cerivastatin 0.3 mg/
day vs. pravastatin
20 mg/day vs. diet
Hyperlipidemia (total
cholesterol 220 mg/dl)
No significant difference in carotid
IMT was seen between the 3
modalities after 6 months:
- Cerivastatin: 1.1% increase (from
0.87  0.21 to 0.88  0.22 mm),
- Pravastatin: 1.8% increase (from 1.09
 0.36 to 1.11  0.38 mm),
- Diet: 1.1% increase (from 0.89 
0.26 to 0.90  0.24 mm).
PHYLLIS43
(2004)
508 patients 4 groups:
hydrochlorothiazide
alone/plus
pravastatin,
fosinopril alone/
plus pravastatin for
2.6 years
Hypercholesterolemia,
hypertension,
asymptomatic carotid
atherosclerosis (maximum
carotid IMT: 1.3-4.0 mm)
a) Hydrochlorothiazide alone: CBM-
max
j significantly (P  .03) pro-
gressed by 0.010  0.004 mm/yr
b) Fosinopril alone vs. hydrochlo-
rothiazide alone: CBMmax
j differ-
ence  0.012 mm/yr (P  .03)
c) Hydrochlorothiazide  pravastatin
vs. hydrochlorothiazide alone:
CBMmax
j difference  0.012
mm/yr, P  .03
d) Fosinopril  pravastatin vs. hydro-
chlorothiazide alone: CBMmax
j dif-
ference  0.012 mm/yr, P  .03
a) The annual progression in the
mean carotid bifurcation IMT was
significantly lower for the hydro-
chlorothiazide  pravastatin vs.
hydrochlorothiazide alone groups
(P  .037).
b) The annual progression in the
mean carotid bifurcation IMT was
significantly lower in the group
receiving fosinopril  pravastatin
compared with the group receiving
hydrochlorothiazide alone (P 
.007).
c) No comparison was made between
the 2 fosinopril groups (with/with-
out pravastatin).
HYRIM44
(2005)
285 patientsk
(142 on
fluvastatin, 143
on placebo)
Fluvastatin 40 mg/
day vs. placebo for 4
years
Hypercholesterolemia and
hypertension without
evidence of cardiovascular
disease
- Fluvastatin significantly reduced
CCA IMT progression compared
with placebo (0.049 vs. 0.076 mm,
P  .0297).
- Fluvastatin significantly reduced ca-
rotid bulb IMT progression com-
pared with placebo (mean difference
0.074 mm, 95% CI  0.146 to
0.021, p0.0214)
Reid et al36
(2005)
54 patients (28
on pravastatin,
26 on placebo)
Pravastatin 40 mg/
day or placebo for 9
months
Evidence of carotid
atherosclerosis by carotid
duplex ultrasonography
- A significant reduction in carotid
IMT was observed in the pravastatin
compared with the placebo group at
3 months (p0.016), 6 months (P
 .011), and 9 months (P  .01).
- Carotid IMT at 6 months: 0.09
(from 1.53 to 1.44 mm) vs. 0.02
(from 1.52 to 1.54 mm) mm, for
pravastatin and placebo, respectively
(P  .011)
- Carotid IMT at 9 months: 0.16
(from 1.53 to 1.37 mm) vs. 0.05
(from 1.52 to 1.47 mm) mm, for
pravastatin and placebo, respectively
(P  .01)
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Takahashi
et al45
(2005)
45 patients (15
on simvastatin,
15 on
pravastatin, 15
controls)
Simvastatin 5-10 mg/
day vs. pravastatin
10-20 mg/day vs.
control
Type 2 diabetes and
hypercholesterolemia
a) Simvastatin significantly reduced
the rate of increase of the right and
mean CCA IMT compared with
controls (from 1.0290.131 to
1.0420.132 mm vs. from
1.0110.160 to 1.0400.159
mm, respectively, P  .001)
b) Pravastatin reduced the rate of in-
crease in the right, left and mean
CCA IMT compared with controls
(from 1.0770.171 to
1.0970.171 vs. 1.0110.160 to
1.0400.159 mm, respectively, P
 .05).
- Simvastatin had a more significantly
inhibitory effect than pravastatin on
the rate of increase in the right CCA
(P  .05) and mean (P  .01) IMT.
Yokoyama
et al37
(2005)
40 patients (20
on fluvastatin,
20 controls)
Fluvastatin 40 mg/
day for 12 months
vs. controls
Hypecholesterolemia Mean carotid IMT decreased from
0.90  0.26 to 0.86  0.27 mm
(4.4% decrease; P  .05), while it
increased from 0.87  0.25 to 0.92
 0.27 mm (5.7% increase; P 
.05), for fluvastatin and control
groups, respectively.
Watanabe
et al48
(2005)
60 patients (30
on pravastatin,
30 on diet)
Pravastatin 10-20
mg/day for 6
months vs. diet
CHD without
hypercholesterolemia (total
cholesterol  220 mg/dl)
- Carotid IMTmax for pravastatin:
from 2.19 (range: 1.86-2.57) to
2.27 (range: 2.00-2.69) mm, P not
significant (P value not given).
- Carotid IMTmax for diet: from 2.07
(range 1.68-2.42) to 1.91 (range:
1.64-2.31) mm, P not significant (P
value not given).
Ainsworth
et al38
(2005)
38 patients (17
on atorvastatin,
21 on placebo)
80 mg atorvastatin vs.
placebo for 3
months
Carotid stenosis  60% Rate of progression of carotid plaque
volume: 90.25  85.12 vs. 16.81
 74.10 mm3, for atorvastatin and
placebo, respectively (P  .0001).
PREVEND
IT49
(2005)
642 patients (317
on pravastatin,
325 on
placebo)
Pravastatin 40 mg/
day for 4 years vs.
placebo
Microalbuminuria without
hypertension or
hypercholesterolemia
a) Carotid IMT: from 0.77  0.18 to
0.81  0.16 mm vs. 0.77  0.18
to 0.81  0.17 mm for pravastatin
and placebo, respectively (P not
significant).
b) Mean change in IMT: 0.039 
0.009 vs. 0.035  0.009 mm, for
pravastatin and placebo, respec-
tively (P not significant).
ACAPS: Asymptomatic Carotid Artery Progression Study, IMT: Intima Media Thickness, PLAC-II: Pravastatin, Lipids, and Atherosclerosis in the Carotid
Arteries-II study, CHD: coronary heart disease, MI: myocardial infarction, LDL: Low density lipoprotein, CCA: Common Carotid Artery, KAPS: Kuopio
Atherosclerosis Prevention Study, CI: Confidence Interval, CAIUS: Carotid Atherosclerosis Italian Ultrasound Study, MARS: Monitored Atherosclerosis
Regression Study, LIPID: Long-term Intervention with Pravastatin in IschaemicDisease study, SE: Standard Error, REGRESS: RegressionGrowth Evaluation
Statin Study, PAD: Peripheral arterial disease, BCAPS: Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study, ASAP: Atorvastatin versus
Simvastatin on Atherosclerosis Progression, ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol, FAST:
Fukuoka Atherosclerosis Trial, PHYLLIS: Plaque Hypertension Lipid-Lowering Italian Study, HYRIM: Hypertension High Risk Management study,
PREVEND IT: Prevention of Renal and Vascular End Stage Disease Intervention Trial
aAlthough initially 445 of the 919 participants were women, 117 on estrogen replacement therapy at baseline were excluded from the final analysis due to the
reported finding that non-contraceptive estrogen is associated with IMT regression (9 m/y).21 Therefore, on the whole 802 patients were studied.
bThe dose was increased to 40mg/day if LDL cholesterol did not fall below 110mg/dl, or decreased to 10mg/day if LDL cholesterol had fallen below 90mg/dl.
cInitially 447 were enrolled in the study but 424 patients were included in the statistical analysis.
dOf the 305 patients, 269 were followed up for the whole 3 years.
eAlthough the original REGRESS study66 included 885 patients, this trial included only the 255 patients who underwent ultrasound scans at baseline, at 6, 12,
18 and 24 months.
fCR/XL: Controlled Release/Extended Release
gOf the 161 patients that entered the trial, only 138 were eligible at the 12-month follow-up.
hA total of 250 patients entered the trial, but only 182 of them completed it.
iCerivastatin patients were switched to simvastatin 20 mg/day after a mean follow-up of 15.4 months when cerivastatin was withdrawn from the market due
to reports of serious morbidity and mortality related to the drug.
jCBMmax : CBMmax was the primary outcome in this study. It was defined as the rate of change in mean maximum IMT of the 8 far and near walls in distal
common carotids and bifurcations bilaterally.
kAlthough 568 patients were included in the trial, the remaining 283 patients are not included because of potential bias by additional “lifestyle” influence.
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4S51 (1994) 4,444 patients (2,221
on simvastatin, 2,223
on placebo)
Simvastatin 10 - 40
mg/day vs.
placebo for a mean
of 5.4 years
Angina pectoris or
previous MI and
serum cholesterol
5.5-8.0 mmol/l
Fatal or nonfatal cerebrovascular events
(TIA, unclassified, intervention-
associated, hemorrhagic, embolic
and non-embolic stroke): 70 vs. 98
patients, for simvastatin and placebo,
respectively (relative risk: 0.70; 95%
CI  0.52 – 0.96; P  .024).
LRT63
(1994)
404 patients (203 on
lovastatin, 201 on
placebo)
40 mg twice/day
lovastatin vs.
placebo for 6
months
CHD patients
undergoing
coronary
angioplasty
a) Incidence of stroke: 0% vs. 0.5%, for
lovastatin and placebo, respectively
(P  .50).
b) Number of events: 0 vs. 1, for lova-
statin and placebo, respectively (P
 .50).
ACAPS39
(1994)
919 patientsa (460 on
atorvastatin, 459 on
placebo)
- Initially: lovastatin
20 mg/day
- At 4.5 months up
to 3 years: in-
creased to 40 mg/
day
Evidence of early
carotid
atherosclerosis
using B-mode
ultrasonography
Number of strokes: 0 vs. 4, for the
atorvastatin and placebo groups,
respectively (P  .05).
WOSCOP64
(1995)
6,595 patients (3,302
on pravastatin, 3,293
on placebo)
Pravastatin 40 mg/
day vs. placebo for
a mean period of
4.9 years
Primary prevention
trial
Number of strokes: 46 (6 fatal) vs. 51
(4 fatal), for the pravastatin and
placebo groups, respectively (risk
reduction: 11%, 95% CI  33% to
40%, P  .57)
PLAC I65
(1995)
408 patients (206 on
pravastatin, 202 on
placebo)
Pravastatin 40 mg/
day vs. placebo for
3.0 years
CHD and LDL
130 but  190
mg/dl
Number of strokes: 0 vs. 2, for the
pravastatin and placebo groups,
respectively (P  .21)
KAPS41
(1995)
424 patients (212 on
pravastatin, vs. 212
on placebo)
Pravastatin 40 mg/
day vs. placebo for
3 years
LDL cholesterol 
4.0 mmol/l and
total cholesterol
7.5 mmol/lt
Number of strokes: 2 vs. 4, for the
pravastatin and placebo groups,
respectively (P not significant, P
value not mentioned)
REGRESS66
(1995)
885 patientsb (450 on
pravastatin, 434 on
placebo)
Pravastatin 40 mg/
day or placebo for
2 years
Hypercholesterolemia
(155-310 mg/dl)
and coronary
atherosclerosis as
defined by
coronary
angiography
Number of cerebrovascular events
(strokes and TIAs): 3 vs. 5, for
pravastatin and placebo, respectively
(P not significant, P value not
mentioned).
CARE52
(1996)
4,159 patients (2,081
on pravastatin, 2,078
on placebo)
Pravastatin 40 mg/
day vs. placebo for
a mean period of
5.0 years
Patients with previous
MI, total
cholesterol  240
mg/dl and LDL 
115-174 mg/dl
Incidence of stroke: 2.6% vs. 3.8% (or
54 vs. 78 patients), for pravastatin
and placebo, respectively (risk
reduction: 31%; 95% CI  3% - 52%;
P  .03).
Post-CABG67
(1997)
1,351 patients (676 on
aggressive vs. 675 on
moderate lovastatin
therapy)
Lovastatin 76 12.6
mg/day
(aggressive) vs. 4
 1.25 mg/day
(moderate) for 4.3
years
Patients with previous
CAGB and
LDL130-175
mg/dl
Number of strokes: 18 vs. 16, or 2.3%
vs. 2.2%, in the aggressive and
moderate lovastatin groups,
respectively (P  .48).
AFCAPS/
TexCAPS68
(1998)
6,605 patients (3,304
on lovastatin, 3,301
on placebo)
Lovastatin 20-40
mg/day or
placebo for a mean
5.2 years
Hyperlipidemia and
low HDL
Incidence of stroke: 14 vs. 17, for
lovastatin and placebo, respectively
(P not significant).
LIPID
(1998)25
(2000)53
9,014 patients (4,512
on pravastatin, 4,502
on placebo)
Pravastatin 40 mg/
day vs. placebo for
a mean period of
6.1 years
MI or hospitalization
for unstable angina
- Incidence of stroke: 3.7% vs. 4.5% for
pravastatin and placebo, respectively
(risk reduction: 19%; 95% CI  0 -
34%; P  .048)
- Fatal strokes: 22 vs. 27 for pravasta-
tin and placebo, respectively (P 
.001).
- Non-hemorrhagic strokes: 3.4% vs.
4.4% for pravastatin and placebo,
respectively (risk reduction: 23%;
95% CI  5-38%; P  .02).
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- It was estimated that over a period of
6.1 years 30 deaths, 28 non-fatal
MIs, and 9 non-fatal strokes were
avoided (with allowance for multiple
events in each patient) in 48 patients
for every 1,000 randomly assigned to
treatment with pravastatin.
- Pravastatin had no effect on hemor-
rhagic stroke (incidence: 0.2% vs.
0.4% in the placebo and pravastatin
groups, respectively; P  .28)
SCAT69
(2000)
460 patients (230 on
simvastatin, 230 on
placebo)
Simvastatin 10-40
mg / Enalapril
2.5-10 mg twice/
day vs. placebo for
4.0 years
Coronary
atherosclerosis and
normocholesterolemia
Incidence of stroke: 2% vs. 3% (or 4 vs.
7 events), for simvastatin and
placebo, respectively (P  .544).
GISSI70
(2000)
4,271 patients (2,138
on pravastatin, 2,133
on placebo)
Pravastatin 20 mg/
day or placebo for
23.0  6.7
months (median
24.3 months)
Previous MI and total
cholesterol  200
mg/dl
Number of strokes: 20 vs. 19, for the
pravastatin and placebo groups,
respectively (P not significant).
MIRACL
(2001)54
(2002)55
3,086 patients (1,538
on atorvastatin, 1,548
on placebo)
Atorvastatin 80 mg/
day vs. placebo for
16 weeks
Unstable angina or
non-Q MI
a) Number of strokes: 12 vs. 24, for
atorvastatin and placebo, respec-
tively (relative risk: 0.49; 95% CI 
0.24 - 0.98; P  .045).
b) Non-fatal strokes: 9 vs. 22 patients
for atorvastatin and placebo, re-
spectively (relative risk: 0.40; 95%
CI  0.19 - 0.88; P  .02).
ALLHAT71
(2002)
10,355 patients (5,170
on pravastatin, 5,185
on placebo)
Pravastatin 40 mg/
day vs. no statin
for a mean follow-
up of 4.8 years
Hypertension and
LDL120-189
mg/dl
Number of strokes: 209 vs. 231 events
for pravastatin and placebo,
respectively (relative risk: 0.91; 95%
CI  0.75 - 1.09; P  .31).
HPS56
(2002)
20,536 patients (10,269
on simvastatin,
10,267 on placebo
Simvastatin 40 mg/
day or placebo for
5.0 years (mean)
CHD, other arterial
occlusive disease or
diabetes
a) Incidence of fatal or non-fatal first
stroke: 4.3% vs. 5.7%, or 444 vs.
585 patients, for simvastatin and
placebo, respectively (P  .0001).
b) Incidence of ischemic stroke was
reduced by 30% (290 vs. 409 pa-
tients or 2.8% vs. 4.0% for simvasta-
tin and placebo, respectively, P 
.0001).
GREACE57
(2002)
1,600 patients (800 on
atorvastatin, 800 on
placebo
Atorvastatin 10-80
mg/day vs.
placebo for 3.0
years
CHD Fatal and non-fatal strokes: 9 vs. 17,
for atorvastatin and placebo,
respectively (risk reduction: 0.53;
95% CI  0.30 - 0.82; P  .034)
PROSPER72
(2002)
5,804 patients (2,891
on pravastatin, 2,913
on placebo)
Pravastatin 40 mg/
day vs. placebo for
3.2 years
Age: 70-82 yrs,
primary and
secondary
prevention of
vascular disease
Number of strokes: 135 vs. 131, for
pravastatin and placebo, respectively
(HR 1.03; 95% CI  0.81 - 1.31;
P  .8).
ASCOT-
LLA58
(2003)
10,305 patients (5,168
on atorvastatin, 5,137
on placebo patients)
Atorvastatin 10 mg/
day or placebo for
3.3 years
Hypertension  at
least 2 other
cardiovascular risk
factors
Fatal and non-fatal strokes: 89 vs. 121
in the simvastatin and placebo
groups, respectively (HR  0.73;
95% CI  0.56 - 0.96; P  .024)
REVERSAL73
(2004)
654 patients (327 on
pravastatin, 327 on
atorvastatin)
Pravastatin 40 mg/
day or atorvastatin
80 mg/day for 18
months
CHD Number of strokes: 1 vs. 1 (or 0.3% for
both groups) for pravastatin and
atorvastatin respectively.
ALLIANCE74
(2004)
2,442 CHD patients
(1,217 on
atorvastatin, 1225 on
usual care)
Atorvastatin 40.5
mg/day (median
dose) vs. usual
care for 54.3
CHD Number of strokes: 35 vs. 39 (or 2.9%
vs. 3.2%) for the atorvastatin and
usual care groups, respectively (HR
 0.87; 95% CI  0.55 - 1.38; P months (median) .552).
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CARDS59
(2004)
2,838 patients (1,428
on atorvastatin, 1,410
on placebo)
Atorvastatin 10 mg/
day vs. placebo for
3.9 yrs
Diabetes, age 40-75
years, no
documented
history of CHD,
LDL4.14 mmol/
l and one of the
following:
retinopathy,
albuminuria,
current smoking,
or hypertension
Incidence of stroke: 1.5% vs. 2.8% (or
21 vs. 35 patients), for atorvastatin
and placebo, respectively (HR: 0.52;
95% CI  0.31 - 0.89; P  .001)
A to Z trial75
(2004)
4,497 patientsc (2,265
on intensive vs. 2,232
on less intensive
simvastatin treatment)
2,232 on placebo for
4 months,
followed by
simvastatin 20
mg/day, 2,265 on
simvastatin 40
mg/day for 1
month followed
by simvastatin 80
mg/day for 6-24
months
Non-ST elevation
acute coronary
syndromes
Number of strokes: 28 vs. 35 (or 1.8%
and 1.3%) for the intensive and less
intensive statin regimen groups,
respectively (P  .36).
PROVE IT-
TIMI-2276
(2004)
4,162 patients (2,063
on pravastatin, 2,099
on atorvastatin)
Pravastatin 40 mg/
day or atorvastatin
80 mg/day for 24
months
Acute coronary
syndrome
Number of strokes: 28 vs. 35 (or 1.8%
and 1.3%) for the intensive and less
intensive statin regimen groups,
respectively (P  .36).
TNT
(2005)60
(2006)62
10,001 patients (5006
on low-dose vs. 4,995
on high-dose
atorvastatin)
Atorvastatin 10 mg/
day vs. 80 mg/day
for 4.9 years
(median)
CHD a) Fatal or non-fatal strokes: 155 vs.
117 (or 3.1% vs. 2.3%) for the low-
dose and high-dose atorvastatin
groups, respectively (HR  0.75;
95% CI  0.59 - 0.96; P  .02).
b) Incidence of cerebrovascular events
(stroke or TIA): 3.9% vs. 5.0% (or
196 vs. 252 patients), high- and
low-dose atorvastatin, respectively
(HR: 0.77; 95% CI  0.64 - 0.93;
P  .007)
IDEAL77
(2005)
8,888 patients (4,439
on high-dose
atorvastatin, 4,449 on
usual-dose
simvastatin)
Atorvastatin 80 mg/
day vs. simvastatin
20 mg/day for a
median of 4.8
years (range 4.0-
5.9 years)
Previous MI Fatal or non-fatal strokes: 174 vs. 151
(or 3.9% vs. 3.4%) for simvastatin
and atorvastatin, respectively (HR 
0.87; 95% CI  0.70 - 1.07; P 
.20)
SPARCL61
(2006)
4,731 patients (2,365
on atorvastatin, 2,366
on placebo)
Atorvastatin 80mg/
day vs. placebo
(4.9 yrs)
Stroke or TIA 1-6
months before
study entry
Incidence of fatal or non-fatal stroke:
11.2% vs. 13.1% (or 265 vs. 311
patients), for atorvastatin and
placebo, respectively (5-year absolute
risk reduction: 2.2%, adjusted HR 
0.84; 95% CI  0.71 - 0.99; P 
.03).
4S: Scandinavian Simvastatin Survival Study, MI: Myocardial infarction, TIA: Transient Ischemic Attack, CI: Confidence Interval, LRT: Lovastatin Restenosis
Trial, CHD: Coronary heart disease, ACAPS: Asymptomatic Carotid Artery Progression Study, WOSCOP: West of Scotland Coronary Prevention Study,
PLAC I: Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries-I study, LDL: Low density lipoprotein, KAPS: Kuopio Atherosclerosis Prevention
Study, REGRESS: Regression Growth Evaluation Statin Study, CARE: Cholesterol and Recurrent Events Trial, Post-CABG: Post Coronary Artery Bypass
Graft Trial, AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study, HDL: High density lipoprotein, LIPID: Long-term
Intervention with Pravastatin in Ischaemic Disease, SCAT: Simvastatin/Enalapril Coronary Atherosclerosis Trial, GISSI: Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Miocardico, MIRACL: Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering, ALLHAT: Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial, HPS: Heart Protection Study, GREACE: GREek Atorvastatin and Coronary-Heart-Disease
Evaluation, PROSPER: Prospective Study of Pravastatin in the Elderly at Risk, HR: Hazard Ratio, ASCOT-LLA: Anglo-Scandinavian Cardiac Outcomes
Trial-Lipid Lowering Arm, REVERSAL: Reversal of Atherosclerosis with Aggressive Lipid Lowering, ALLIANCE: Aggressive Lipid-Lowering Initiation
Abates New Cardiac Events study, CARDS: Collaborative Atorvastatin Diabetes Study, PROVE IT-TIMI-22: Pravastatin or Atorvastatin Evaluation and
Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators, TNT: Treating to New Targets, IDEAL: Incremental Decrease in End Points
Through Aggressive Lipid Lowering, SPARCL: Stroke Prevention by Aggressive Reduction in Cholesterol Levels
aInitially 445 of the 919 participants were women. However, 117 on estrogen replacement therapy at baseline were excluded from the final analysis due to the
reported finding that non-contraceptive estrogen is associated with IMT regression (9 m/y).21 Therefore, on the whole 802 patients were studied.
bOne patient in the placebo group withdrew his informed consent immediately after randomization and before medication was started. This patient was
considered non-compliant.
cOf the 4,497 patients initially randomized, 4,493 were included in the final safety analysis (2,230 and 2,263 patients from the low-dose and high-dose statin
groups, respectively).
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ACAPS39
(1994)
919 patientsa (460 on
atorvastatin, 459 on
placebo)
- Initially: lovastatin 20
mg/day
- At 4.5 months up to
3 years: increased to
40 mg/day
Evidence of early carotid
atherosclerosis using
B-mode
ultrasonography
Major cardiovascular events (CHD
mortality, non-fatal MI, or
stroke) occurred in 5 vs. 14
patients in the atorvastatin and
placebo groups, respectively (P
 .04).
PLAC-II40
(1995)
151 patients (75 on
pravastatin, vs. 76 on
placebo)
Pravastatin 20 mg/dayb
vs. placebo for 3
years
Evident CHD or recent
MI and LDL
cholesterol 130
mg/dl
a) A 60% reduction in clinical cor-
onary events (4 vs. 10, or 5.3%
vs. 13.2%, P  .09) and fewer
deaths (3 vs. 5) for pravastatin
and placebo, respectively.
b) A 61% reduction in the com-
bined end point of any coro-
nary event and any death (5 vs.
13 and 7% vs. 17%, respec-
tively, P  .04) for pravastatin
and placebo, respectively.
AFCAPS/
TexCAPS68
(1998)
6,605 patients (3,304
on lovastatin, 3,301
on placebo)
Lovastatin 20-40 mg/
day or placebo for a
mean 5.2 years
Hyperlipidemia and low
HDL
Total number of fatal and non-
fatal cardiovascular events
(including stable angina,
thrombotic cerebrovascular
accidents, TIAs and peripheral
arterial vascular disorders) in the
lovastatin and placebo groups
was 194 and 255, respectively
(P  .003).
LIPID145
(1998)53
(2000)
9,014 patients (4,512
on pravastatin, 4,502
on placebo)
Pravastatin 40 mg/day
vs. placebo for a
mean period of 6.1
years
MI or hospitalization for
unstable angina
Over a period of 6.1 yrs, it was
estimated that 30 deaths, 28
non-fatal MIs, and 9 non-fatal
strokes were avoided (with
allowance for multiple events in
each patient) in 48 patients for
every 1,000 randomly assigned
to treatment with pravastatin.
HPS56
(2002)
20,536 patients
(10,269 on
simvastatin, 10,267
on placebo
Simvastatin 40 mg/day
or placebo for 5.0
years (mean)
CHD, other arterial
occlusive disease or
diabetes
- All-cause mortality was signifi-
cantly reduced (1328 [12.9%]
vs. 1507 [14.7%] deaths, for
simvastatin and placebo, respec-
tively; P  .0003), due to:
i) a significant 18% proportional
reduction in the coronary
death rate (587 [5.7%] vs.
707 [6.9%]; P  .0005),
ii) a marginally significant re-
duction in other vascular
deaths (194 [1.9%] vs 230
[2.2%]; P  .07), and
iii) a non-significant reduction
in non-vascular deaths (547
[5.3%] vs 570 [5.6%]; P 
.4).
- There were highly significant
reductions of about one-quarter
in the first event rate for non-
fatal myocardial infarction or
coronary death (898 [8.7%] vs
1212 [11.8%]; P  .0001), and
for coronary or non-coronary
revascularisation (939 [9.1%] vs
1205 [11.7%]; P  .0001).
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PROVE IT-
TIMI-
2276
(2004)
4,162 patients (2,063
on pravastatin, 2,099
on atorvastatin)
Pravastatin 40 mg/day
or atorvastatin 80
mg/day for 24
months
Acute coronary
syndrome
High-dose atorvastatin was
beneficial compared with
standard-dose pravastatin:
- 14% reduction in the need for
coronary revascularization (P 
.04),
- 29% reduction in the risk of re-
current unstable angina (P 
.02), and
- Marginally significant reduction
in the rates of death from MI
(18%, P  .06), or any cause
(28%, P  .07)].
CARDS59
(2004)
2,838 patients (1,428
on atorvastatin vs.
1,410 on placebo)
Atorvastatin 10 mg/
day vs. placebo for
3.9 yrs
Diabetes, age 40-75
years, no documented
history of CHD,
LDL4.14 mmol/l
and one of the
following:
retinopathy,
albuminuria, current
smoking, or
hypertension
a) Incidence of acute coronary
event: 3.6% vs. 5.5% (or 51 vs.
77 patients) for atorvastatin
and placebo, respectively (HR:
0.64; 95% CI  0.45 - 0.91; P
 .001)
b) Death from any cause: 4.3% vs.
5.8% (or 61 vs. 82 patients) for
atorvastatin and placebo, re-
spectively (HR: 0.73; 95% CI
 0.52 - 1.01; P  .059)
SPARCL61
(2006)
4,731 patients 1-6
months after stroke
or TIA, without
CHD or
hypercholesterolemia
Atorvastatin vs. placebo
(4.9 yrs)
Stroke or TIA 1-6
months before study
entry
a) Major coronary events: 81 vs.
120, or 3.4% vs. 5.1%, for ator-
vastatin and placebo, respec-
tively; adjusted HR  0.65;
95% CI  0.49 - 0.87; P 
.003.
b) Major cardiovascular events:
334 vs. 407, or 14.1% vs.
17.2%, for atorvastatin and pla-
cebo, respectively; adjusted
HR 0.80; 95% CI 0.69 -
0.92; P  .002.
c) Any CHD:i 123 vs. 204, or
5.2% vs. 8.6%, for atorvastatin
and placebo, respectively; ad-
justed HR  0.58; 95% CI 
0.46 - 0.73; P  .001.
TNT60
(2006)
10,001 patients (5,006
low- vs. 4,995 high-
dose atorvastatin)
Atorvastatin 10 vs. 80
mg/day for (4.9 yrs)
CHD a) CHD death: 101 vs. 127, or
2.0% vs. 2.5%, for high- and
low-dose atorvastatin, respec-
tively (HR: 0.80; 95% CI 
0.61 - 1.03; P  .087).
b) Non-fatal MI: 243 vs. 308, or
4.9% vs. 6.2%, for high- and
low-dose atorvastatin, respec-
tively (HR: 0.78; 95% CI 
0.66 - 0.93; P  .004).
c) Major coronary event:ii 335 vs.
418, or 6.7% vs. 8.3%, for high-
and low-dose atorvastatin, re-
spectively (HR: 0.80; 95% CI
 0.69 - 0.92; P  .0019).
ACAPS: Asymptomatic Carotid Artery Progression Study, CHD: coronary heart disease, MI: myocardial infarction, PLAC-II: Pravastatin, Lipids, and
Atherosclerosis in the Carotid Arteries-II study, LDL: Low density lipoprotein, AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention
Study, HDL: High density lipoprotein, TIAs: Transient ischemic attacks, LIPID: Long-term Intervention with Pravastatin in Ischaemic Disease study, HPS:
Heart Protection Study, PROVE IT-TIMI-22: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22
Investigators, CARDS: Collaborative Atorvastatin Diabetes Study, HR: Hazard Ratio, CI: confidence interval, SPARCL: Stroke Prevention by Aggressive
Reduction in Cholesterol Levels, TNT: Treating to New Targets
aAlthough initially 445 of the 919 participants were women, 117 on estrogen replacement therapy at baseline were excluded from the final analysis due to the
reported finding that non-contraceptive estrogen is associated with IMT regression (9 m/y).21 Therefore, on the whole 802 patients were studied.
bThe dose was increased to 40 mg/day if LDL cholesterol did not fall below 110 mg/dl, or decreased to 10 mg/day if LDL cholesterol had fallen below 90
mg/dl.
